<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599751</url>
  </required_header>
  <id_info>
    <org_study_id>ALM-Trio-20-001</org_study_id>
    <nct_id>NCT04599751</nct_id>
  </id_info>
  <brief_title>The Trio Laser Module for Hair Removal Treatment</brief_title>
  <official_title>The Safety and Efficacy of Trio Diode Laser Module for Hair Removal Treatment in All Skin Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alma Lasers</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alma Lasers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to assess the safety and efficacy of hair removal treatments, using the&#xD;
      Trio Laser Module (Alma Lasers).&#xD;
&#xD;
      The study will include 36 subjects that will undergo axilla and bikini line hair removal&#xD;
      treatments. Safety and efficacy will be evaluated 3- months after the last treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Actual">November 16, 2021</completion_date>
  <primary_completion_date type="Actual">October 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hair count</measure>
    <time_frame>3 month after the last treatment</time_frame>
    <description>Change in hair count, preformed by blinded evaluators, based on photographs taken at 3m FU visit compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety- Adverse events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Adverse events and serious AE reported at any time during the trial or follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's assessment of the tolerability to the treatment using a 5-point Likert scale (when &quot;0&quot; indicates &quot;none&quot; and &quot;4&quot; indicates &quot;sever&quot;).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The investigator will assess the treatment area and score treatment related side effects using a 5-point likert scale, before and after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's tolerability to the treatment, using a 5-point Likert scale (when &quot;0&quot; indicates &quot;none&quot; and &quot;4&quot; indicates &quot;sever&quot;).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Subjects will be requested to scale any sensation of stinging, tingling, itching and, burning using the 5-point Likert scale, before and after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject treatment related pain assessment, using VAS ( when &quot;0&quot; indicates &quot;no pain&quot; and &quot;10&quot; &quot; worst possible pain&quot;</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Subjects will be requested to scale their treatment related pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's satisfaction from the treatment, using a 5-point Likert scale (when &quot;1&quot; indicates very dissatisfied and &quot;5&quot; very satisfied)</measure>
    <time_frame>3 months after the last treatment</time_frame>
    <description>Subjects will be requested to scale their satisfaction from the treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hair Removal Treatment</condition>
  <arm_group>
    <arm_group_label>Hair removal treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trio laser module (Alma Lasers)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hair removal treatment</intervention_name>
    <description>Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).</description>
    <arm_group_label>Hair removal treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to undergo hair removal treatments at the Axilla and the Bikini line.&#xD;
&#xD;
          -  Between 18 and 70 years of age.&#xD;
&#xD;
          -  Reasonably good health, as defined by the Investigator.&#xD;
&#xD;
          -  Agrees to avoid tanning during their participation in this study.&#xD;
&#xD;
          -  Agrees to shave the treatment area prior to the treatment visit, according to the&#xD;
             investigator's instructions.&#xD;
&#xD;
          -  Subjects with dark brown hair.&#xD;
&#xD;
          -  Eligible for treatment following a test spot without negative effects.&#xD;
&#xD;
          -  Provided written Informed Consent and photo consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of laser hair removal in the treatment area.&#xD;
&#xD;
          -  Pregnant, lactating or planning to get pregnant within the study period.&#xD;
&#xD;
          -  Unwilling to use a medically acceptable form of birth control at least 3 months prior&#xD;
             to enrollment and during the entire course of the study, if of childbearing age.&#xD;
&#xD;
          -  History of photosensitivity or use of medication with photosensitizing properties.&#xD;
&#xD;
          -  Active infection in the treatment area.&#xD;
&#xD;
          -  History or evidence of any chronic or reoccurring skin disease or disorder affecting&#xD;
             the treatment area.&#xD;
&#xD;
          -  History of keloid scarring or hypertrophic scar formation.&#xD;
&#xD;
          -  Tattoo in the treatment area.&#xD;
&#xD;
          -  Subject has been tanning within the past 30 days.&#xD;
&#xD;
          -  History of confounding cancerous or pre-cancerous skin lesions in the treatment area.&#xD;
&#xD;
          -  History of connective, metabolic or atrophic skin disease.&#xD;
&#xD;
          -  Subject has used prohibited therapies, oral prescription medication, or topical meds&#xD;
             (steroids) on the treatment area within 30 days prior to enrollment.&#xD;
&#xD;
          -  History of autoimmune disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennessee Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwardo Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Care Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

